Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for urologic conditions. Co.'s primary product candidate, vibegron is an oral, once-daily, small molecule that was observed to be selective for the human beta-3 adrenergic receptor in in vitro assays. Vibegron is being developed for various potential indications: overactive bladder (OAB), the treatment of OAB in men with benign prostatic hyperplasia, and the treatment of abdominal pain due to irritable bowel syndrome. In addition, Co.'s second product candidate, URO-902 is a gene therapy that it is developing for patients with OAB who have failed oral pharmacological therapy. We show 12 historical shares outstanding datapoints in our coverage of UROV's shares outstanding history.
Understanding the changing numbers of UROV shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like UROV versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching UROV by allowing them to research UROV shares outstanding history
as well as any other stock in our coverage universe. |
Free UROV Email Alerts:
Video: Shares Outstanding Importance
